Sign In
Sign In
Twelve months ago, the treasury team at Gilead Sciences, Inc., a fast-growing biopharmaceutical business that develops and produces treatments for some of the world’s deadliest diseases, faced some critical challenges. The company brings in close to $10 billion in annual revenue through operations in more than 30 countries. Yet its small treasury staff was spending more time on transaction processing than on analysis, and manual data entry put the company at risk for errors.
Recommended Stories
Covid-19 Impacts on Trade
April activity on a supply chain finance platform indicates how the pandemic is affecting specific industries and regions.
FX Impact on Earnings: Smaller but Still Significant
Nearly one in four large North American companies reported that currency movement had a negative impact on earnings in Q3/2019.
Search for Solutions as the Tsunami Approaches
Companies that may require a loan modification in the next few months should be looking, right now, at exactly what covenant relief they will need, and what concessions lenders may demand in exchange.
Resource Center
falcon-custom-content
Sponsored by Serrala
Preparing your treasury department for what lies ahead means knowing what tools are available, and what s best for your organization.
Treasury & Risk
Don’t miss crucial treasury and finance news along with in-depth analysis and insights you need to make informed treasury decisions. Join Treasury & Risk now!
- Free unlimited access to Treasury & Risk including case studies with corporate innovators, informative newsletters, educational webcasts, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM publications including PropertyCasualty360.com and Law.com.
Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.